REGULATORY

Japan Prepping to Expand Veklury Label beyond Severe COVID-19: PMDA

December 25, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japanese regulators are preparing to expand the label of Gilead Sciences’ antiviral agent Veklury (remdesivir) to allow its use beyond severely ill patients with COVID-19 in alignment with the population of patients in whom the drug’s efficacy and safety were…

To read the full story

PMDA Updates Veklury Label to Allow Its Use in Moderate COVID-19
January 8, 2021

REGULATORY

MHLW to Set Up Expert Panel on Using Disease Registries in Drug Development
January 13, 2026
Chuikyo Moves to Allow Special Mixed-Billing for Santen’s Myopia Drug
January 13, 2026
Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23
January 13, 2026
MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement
January 6, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…